TPSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Tempest Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.60−0.02 (-3.86%)
Close on Oct 19, 2026
- Market cap
- $9.14M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$9.5399 (−94.08%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $9.14M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -226.91%
Fundamentals
- Net income
- -$40.47M
- EPS, diluted
- -$4.48
- Free cash flow
- -$20.73M
- Book value per share
- -$0.07
- Diluted shares
- 15M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$40.64M
Net income
-$40.47M
EPS, diluted
-$4.48
Free cash flow
-$20.73M
Reported periodTrailing twelve months